Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stelara · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Stelara | DRUG | A commercial formulation of ustekinumab for SC control (0.5mg) |
| RT-111 (0.5mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.5mg |
| RT-111 (0.75mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.75mg |
Stelara is a small molecule drug being developed by Rani Therapeutics Holdings, Inc. (ticker: RANI). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied for its pharmacokinetic profile when administered orally via the RaniPill capsule.
Stelara is being investigated for use in healthy volunteers as part of a Phase 1 clinical trial. The study is evaluating the pharmacokinetics of ustekinumab when administered orally via the RaniPill capsule. The drug is not yet approved for any specific disease or condition.
Stelara is being developed by Rani Therapeutics Holdings, Inc., a biopharmaceutical company traded under the ticker symbol RANI. The company is conducting clinical trials to evaluate the drug's pharmacokinetics when delivered orally via its RaniPill capsule technology.
Stelara is in Phase 1 clinical development. The drug is being studied in a completed Phase 1 trial that enrolled 55 healthy volunteers. It is an investigational drug and has not been approved by regulatory authorities.
Stelara has one completed clinical trial, NCT05890118, titled "Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule." This Phase 1 study enrolled 55 healthy volunteers and was an uncontrolled, non-randomized, non-double-blind trial.
Stelara is being studied as an oral formulation of ustekinumab, which is the active substance in the trial. The Phase 1 study evaluates the pharmacokinetics of ustekinumab when delivered via the RaniPill capsule, indicating that Stelara is a branded oral version of this molecule.